Abstract
ObjectiveCervical cancer is a frequently encountered gynecological malignancy as a major contributor to cancer-related deaths in women. This study focuses on how miR-193b promotes cervical cancer aggressiveness as well as the role of m6A in miR-193b silencing.MethodsCervical cancer samples and the matching adjacent normal cervical tissues were used to determine the significance of miR-193b in cervical cancer. The CCK-8 assay, cell cycle analysis, qRT-PCR, Western blot assay, IHC, RIP, and xenograft models were utilized to explore the impact of miR-193b in cervical cancer and how m6A regulates miR-193b expression. Luciferase reporter assays, qRT-PCR, and Western blotting were enlisted to study the interaction between miR-193b and CCND1.ResultsOur study suggested that lower miR-193b expressions were strongly linked to more advanced cervical cancer stages and the presence of deeper stromal invasion. miR-193b functions as a tumor suppressor that is regulated by m6A methylation in cervical tumors. METTL3 modulates miR-193b mature process in an m6A-dependent manner. Reintroduction of miR-193b profoundly inhibits tumorigenesis of cervical cancer cells both in vivo and in vitro through CCND1 targeting.Conclusionsm6A associated downregulation of miR-193b promotes cervical cancer aggressiveness by targeting CCND1.
Highlights
Cervical cancer is a frequently encountered gynecological malignancy as a primary cause of cancerassociated mortality in women [1]
Determination of the Clinical Significance of miR-193b in Cervical Cancer qRT-PCR was used to determine miR-193b levels in clinical cervical cancer specimens and the matching surrounding normal cervical tissues (N = 41). 26 of these tumor samples (63%) contained low miR-193b levels. These findings indicate that miR-193b suppression may be a key feature leading to the progression of human cervical cancer
These results show that miR-193b silencing played a crucial part during cervical cancer development
Summary
Cervical cancer is a frequently encountered gynecological malignancy as a primary cause of cancerassociated mortality in women [1]. Most patients respond to standard treatments which include surgery and radiotherapy. There remains a substantial risk of tumor relapse in patients who develop locally advanced cervical cancer with high risks such as positive lymph miR-193b Promotes Cervical Cancer Aggressiveness nodes or positive surgical margins. Among these groups of patients, relapse rates exceeding 50% after standard treatments have been documented. The identification of novel therapeutic methods is critical, and inevitably requires a deeper grasp of cervical cancer biology
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
